- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02693535
TAPUR: Testando o uso de medicamentos aprovados pela Food and Drug Administration (FDA) que visam uma anormalidade específica em um gene tumoral em pessoas com câncer em estágio avançado (TAPUR)
Estudo de registro de utilização de agentes e perfis direcionados (TAPUR)
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
********************************************************************
Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.
********************************************************************
Visão geral do estudo
Status
Intervenção / Tratamento
- Medicamento: Sunitinib (CLOSED TO ENROLLMENT)
- Medicamento: Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)
- Medicamento: Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- Medicamento: Olaparib (CLOSED TO ENROLLMENT)
- Medicamento: Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)
- Medicamento: Abemaciclib (CLOSED TO ENROLLMENT)
- Medicamento: Talazoparib (CLOSED TO ENROLLMENT)
- Medicamento: Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT)
- Medicamento: Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)
- Medicamento: Futibatinib
- Medicamento: Dabrafenib plus Trametinib
- Medicamento: Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Descrição detalhada
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Laurie Smith, MA
- Número de telefone: www.tapur.org
- E-mail: tapur@asco.org
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- Recrutamento
- University of Alabama at Birmingham Comprehensive Cancer Center
-
Investigador principal:
- Mehmet Akce, MD
-
Contato:
- Kun Yuan
- Número de telefone: 205-644-2584
- E-mail: kunyuan@uabmc.edu
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85338
- Recrutamento
- Cancer Treatment Centers of America-Phoenix
-
Investigador principal:
- Sagun Shrestha, MD
-
Contato:
- Alex Lizzul
- Número de telefone: 602-872-5654
- E-mail: alizzul@coh.org
-
-
California
-
Auburn, California, Estados Unidos, 95602
- Recrutamento
- Sutter Auburn
-
Contato:
- Kirsten Babski
- Número de telefone: 916-878-4990
- E-mail: BabskiK@sutterhealth.org
-
Investigador principal:
- Nitin Rohatgi, MD
-
Berkeley, California, Estados Unidos, 94705
- Recrutamento
- Sutter Alta Bates
-
Contato:
- Christopher Tang
- Número de telefone: 510-204-3428
- E-mail: Christopher.Tang@sutterhealth.org
-
Investigador principal:
- Nitin Rohatgi, MD
-
Los Angeles, California, Estados Unidos, 90025
- Recrutamento
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
-
Contato:
- Teri Mata
- Número de telefone: 310-231-2115
- E-mail: tmata@theangelesclinic.org
-
Investigador principal:
- Omid Hamid, MD
-
Oakland, California, Estados Unidos, 94611
- Recrutamento
- Kaiser Permanente - Oakland Medical Center
-
Contato:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Investigador principal:
- Jennifer M Suga, MD
-
Palo Alto, California, Estados Unidos, 94301
- Recrutamento
- Sutter Palo Alto Medical Foundation: Palo Alto
-
Contato:
- E-mail: clinicaltrials@pamf.org
-
Roseville, California, Estados Unidos, 95661
- Recrutamento
- Kaiser Permanente - Roseville Medical Center
-
Contato:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Investigador principal:
- Jennifer M Suga, MD
-
Roseville, California, Estados Unidos, 95661
- Recrutamento
- Sutter Roseville
-
Contato:
- Kirsten Babski
- Número de telefone: 916-878-4990
- E-mail: BabskiK@sutterhealth.org
-
Investigador principal:
- Nitin Rohatgi, MD
-
Sacramento, California, Estados Unidos, 95814
- Recrutamento
- Kaiser Permanente - Sacramento Medical Center
-
Contato:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Investigador principal:
- Jennifer M Suga, MD
-
Sacramento, California, Estados Unidos, 95816
- Recrutamento
- Sutter Sacramento
-
Contato:
- E-mail: SIMR@sutterhealth.org
-
Investigador principal:
- Nitin Rohatgi, MD
-
San Francisco, California, Estados Unidos, 94115
- Recrutamento
- California Pacific Medical Center Research Institute
-
Contato:
- Número de telefone: 415-600-1654
- E-mail: clinicalresearch@sutterhealth.org
-
Investigador principal:
- Nitin Rohatgi, MD
-
San Francisco, California, Estados Unidos, 94080
- Recrutamento
- Kaiser Permanente - South San Francisco Medical Center
-
Contato:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Investigador principal:
- Jennifer M Suga, MD
-
San Francisco, California, Estados Unidos, 94115
- Recrutamento
- Kaiser Permanente - San Francisco Medical Center
-
Contato:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Investigador principal:
- Jennifer M Suga, MD
-
San Francisco, California, Estados Unidos, 94115
- Recrutamento
- Sutter Cancer Research Consortium
-
Contato:
- Laurel Brechtel
- Número de telefone: 415-600-1654
- E-mail: BrechtLa@cpmcri.org
-
Investigador principal:
- Stacy D'Andre, MD
-
San Jose, California, Estados Unidos, 95119
- Recrutamento
- Kaiser Permanente - San Jose Medical Center
-
Contato:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Investigador principal:
- Jennifer M Suga, MD
-
San Leandro, California, Estados Unidos, 94577
- Recrutamento
- Kaiser Permanente - San Leandro Medical Center
-
Contato:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Investigador principal:
- Jennifer M Suga, MD
-
Santa Barbara, California, Estados Unidos, 93105
- Recrutamento
- Sutter Sansum Clinic
-
Investigador principal:
- Nitin Rohatgi, MD
-
Contato:
- Selina Perez
- Número de telefone: 831-458-5837
- E-mail: Selina.Perez@sutterhealth.org
-
Santa Clara, California, Estados Unidos, 95051
- Recrutamento
- Kaiser Permanente - Santa Clara Medical Center
-
Contato:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Investigador principal:
- Jennifer M Suga, MD
-
Santa Cruz, California, Estados Unidos, 95065
- Recrutamento
- Sutter Palo Alto Medical Foundation: Santa Cruz
-
Contato:
- E-mail: clinicaltrials@pamf.org
-
Santa Cruz, California, Estados Unidos, 994538
- Recrutamento
- Sutter Palo Alto Medical Foundation: Fremont
-
Contato:
- E-mail: clinicaltrials@pamf.org
-
Sunnyvale, California, Estados Unidos, 94086
- Recrutamento
- Sutter Palo Alto Medical Foundation: Sunnyvale
-
Contato:
- E-mail: clinicaltrials@pamf.org
-
Vallejo, California, Estados Unidos, 94589
- Recrutamento
- Kaiser Permanente - Vallejo Medical Center
-
Contato:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Investigador principal:
- Jennifer M. Suga, MD
-
Walnut Creek, California, Estados Unidos, 94596
- Recrutamento
- Kaiser Permanente - Walnut Creek Medical Center
-
Contato:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Investigador principal:
- Jennifer M Suga, MD
-
-
Connecticut
-
Bridgeport, Connecticut, Estados Unidos, 06606
- Recrutamento
- Saint Vincent's Medical Center (SVMC)
-
Contato:
- Número de telefone: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Investigador principal:
- Wylie Hosmer, MD
-
Hartford, Connecticut, Estados Unidos, 06102
- Recrutamento
- Hartford Hospital
-
Contato:
- Número de telefone: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Investigador principal:
- Wylie Hosmer, MD
-
Meriden, Connecticut, Estados Unidos, 06451
- Recrutamento
- Midstate Medical Center (MSMC)
-
Contato:
- Número de telefone: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Investigador principal:
- Wylie Hosmer, MD
-
New Britain, Connecticut, Estados Unidos, 06053
- Recrutamento
- The Hospital of Central Connecticut (HOCC) Cancer Center
-
Investigador principal:
- Wylie Hosmer, MD
-
Contato:
- Número de telefone: 8609724700
- E-mail: CancerResearchSupport@hhchealth.org
-
Norwich, Connecticut, Estados Unidos, 06360
- Recrutamento
- William W. Backus Hospital
-
Contato:
- Número de telefone: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Investigador principal:
- Wylie Hosmer, MD
-
Torrington, Connecticut, Estados Unidos, 06790
- Recrutamento
- Charlotte Hungerford
-
Contato:
- Número de telefone: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Investigador principal:
- Wylie Hosmer, MD
-
Willimantic, Connecticut, Estados Unidos, 06226
- Recrutamento
- Windham Hospital (WH)
-
Contato:
- Número de telefone: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Investigador principal:
- Wylie Hosmer, MD
-
-
Florida
-
Altamonte Springs, Florida, Estados Unidos, 32701
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Aventura, Florida, Estados Unidos, 33180
- Recrutamento
- University of Miami/Sylvester Cancer Institute - Aventura
-
Contato:
- Carolina Troche, BS
- Número de telefone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Investigador principal:
- Carmen Calfa, MD
-
Bonita Springs, Florida, Estados Unidos, 34135
- Ativo, não recrutando
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Bradenton, Florida, Estados Unidos, 34211
- Ativo, não recrutando
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Brandon, Florida, Estados Unidos, 33511
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Cape Coral, Florida, Estados Unidos, 33909
- Ativo, não recrutando
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Clearwater, Florida, Estados Unidos, 33761
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Coral Gables, Florida, Estados Unidos, 33146
- Recrutamento
- University of Miami/Sylvester Cancer Institute - Lennar
-
Contato:
- Carolina Troche, BS
- Número de telefone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Investigador principal:
- Carmen Calfa, MD
-
Deerfield Beach, Florida, Estados Unidos, 33442
- Recrutamento
- University of Miami/Sylvester Cancer Institute - Deerfield Beach
-
Contato:
- Carolina Troche, BS
- Número de telefone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Investigador principal:
- Carmen Calfa, MD
-
Fort Lauderdale, Florida, Estados Unidos, 33308
- Recrutamento
- Holy Cross Hospital
-
Investigador principal:
- Zdenka Segota, MD
-
Contato:
- Número de telefone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Fort Myers, Florida, Estados Unidos, 33901
- Ativo, não recrutando
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Fort Myers, Florida, Estados Unidos, 33905
- Ativo, não recrutando
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Fort Myers, Florida, Estados Unidos, 33908
- Ativo, não recrutando
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Gainesville, Florida, Estados Unidos, 32610
- Recrutamento
- University of Florida Health
-
Investigador principal:
- Thomas George, MD
-
Contato:
- Anna Kukulka, RN, BSN
- Número de telefone: 352-293-2551
- E-mail: akukulka@ufl.edu
-
Gainesville, Florida, Estados Unidos, 32605
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Largo, Florida, Estados Unidos, 33770
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Lecanto, Florida, Estados Unidos, 34461
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Miami, Florida, Estados Unidos, 33136
- Recrutamento
- University of Miami Sylvester Comprehensive Cancer Center
-
Contato:
- Carolina Troche, BS
- Número de telefone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Investigador principal:
- Carmen Calfa, MD
-
Miami, Florida, Estados Unidos, 33136
- Recrutamento
- University of Miami/Sylvester Cancer Institute - Alex's Place
-
Contato:
- Carolina Troche, BS
- Número de telefone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Investigador principal:
- Carmen Calfa, MD
-
Miami, Florida, Estados Unidos, 33136
- Recrutamento
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building
-
Contato:
- Carolina Troche, BS
- Número de telefone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Investigador principal:
- Carmen Calfa, MD
-
Miami, Florida, Estados Unidos, 33176
- Recrutamento
- University of Miami/Sylvester Cancer Institute - Kendall
-
Contato:
- Carolina Troche, BS
- Número de telefone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Investigador principal:
- Carmen Calfa, MD
-
Miami, Florida, Estados Unidos, 33181
- Recrutamento
- University of Miami/Sylvester Cancer Institute - Sole Mia
-
Contato:
- Carolina Troche, BS
- Número de telefone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Investigador principal:
- Carmen Calfa, MD
-
Naples, Florida, Estados Unidos, 34102
- Ativo, não recrutando
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Ocala, Florida, Estados Unidos, 34474
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Orange City, Florida, Estados Unidos, 32763
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Orlando, Florida, Estados Unidos, 32806
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Plantation, Florida, Estados Unidos, 33324
- Recrutamento
- University of Miami/Sylvester Cancer Institute - Plantation
-
Contato:
- Carolina Troche, BS
- Número de telefone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Investigador principal:
- Carmen Calfa, MD
-
Port Charlotte, Florida, Estados Unidos, 33980
- Ativo, não recrutando
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Sarasota, Florida, Estados Unidos, 34236
- Ativo, não recrutando
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Sarasota, Florida, Estados Unidos, 34239
- Ativo, não recrutando
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
St. Petersburg, Florida, Estados Unidos, 33701
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Tampa, Florida, Estados Unidos, 33607
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Tavares, Florida, Estados Unidos, 32778
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
The Villages, Florida, Estados Unidos, 32159
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Trinity, Florida, Estados Unidos, 34655
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Venice, Florida, Estados Unidos, 34285
- Ativo, não recrutando
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Venice, Florida, Estados Unidos, 34292
- Ativo, não recrutando
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Winter Park, Florida, Estados Unidos, 32789
- Ativo, não recrutando
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Recrutamento
- Emory University Winship Cancer Institute
-
Investigador principal:
- Olatunji Alese, MD
-
Contato:
- Krystal Bagley
- Número de telefone: 404-778-8670
- E-mail: krystal.joi.bagley@emory.edu
-
Atlanta, Georgia, Estados Unidos, 30265
- Recrutamento
- Cancer Treatment Centers of America - Atlanta
-
Investigador principal:
- Bamidele Adesunloye, MD
-
Contato:
- Elizabeth McKoy, RN, BSN
- Número de telefone: 770-400-7177
- E-mail: emckoy@coh.org
-
Savannah, Georgia, Estados Unidos, 31405
- Recrutamento
- Summit Cancer Care
-
Investigador principal:
- Mark Taylor, MD
-
Contato:
- Stephanie Smith, RN, MSN, OCN
- Número de telefone: 9128195723
- E-mail: smiths1@sjchs.org
-
Savannah, Georgia, Estados Unidos, 31405
- Recrutamento
- Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion
-
Investigador principal:
- Mark Taylor, MD
-
Contato:
- Stephanie Smith, RN, MSN, OCN
- Número de telefone: 9128195723
- E-mail: smiths1@sjchs.org
-
Savannah, Georgia, Estados Unidos, 31405
- Recrutamento
- Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute
-
Investigador principal:
- Mark Taylor, MD
-
Contato:
- Stephanie Smith, RN, MSN, OCN
- Número de telefone: 19128195723
- E-mail: smiths1@sjchs.org
-
Savannah, Georgia, Estados Unidos, 31405
- Recrutamento
- Lewis Cancer & Research Pavilion
-
Contato:
- Stephanie Smith, RN, MSN, OCN
- Número de telefone: 912-819-5723
- E-mail: smiths1@sjchs.org
-
Investigador principal:
- Mark Taylor, MD
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96813
- Recrutamento
- The Queen's Medical Center - POB I
-
Investigador principal:
- Jared Acoba, MD
-
Contato:
- Tim Kelleher
- Número de telefone: 8086918582
- E-mail: tkelleher@queens.org
-
Honolulu, Hawaii, Estados Unidos, 96813
- Recrutamento
- The Queen's Medical Center - Punchbowl
-
Investigador principal:
- Jared Acoba, MD
-
Contato:
- Tim Kelleher
- Número de telefone: 808 691-8582
- E-mail: tkelleher@queens.org
-
Honolulu, Hawaii, Estados Unidos, 96817
- Recrutamento
- The Queen's Medical Center - Kuakini
-
Investigador principal:
- Jared Acoba, MD
-
Contato:
- Tim Kelleher
- Número de telefone: 8086918582
- E-mail: tkelleher@queens.org
-
‘Ewa Beach, Hawaii, Estados Unidos, 96706
- Recrutamento
- The Queen's Medical Center - West Oahu
-
Investigador principal:
- Jared Acoba, MD
-
Contato:
- Tim Kelleher
- Número de telefone: 8086918582
- E-mail: tkelleher@queens.org
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60099
- Recrutamento
- Cancer Treatment Centers of America-Chicago
-
Investigador principal:
- Evan Pisick, MD
-
Contato:
- Office of Clinical Trials
- Número de telefone: 847-731-1777
- E-mail: CHIResearch@coh.org
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46250
- Recrutamento
- Community Health Network (The University of Texas MD Anderson Cancer Center)
-
Investigador principal:
- Funda Meric-Bernstam, MD
-
Contato:
- Kshipra Sharma, MPH, MS
- Número de telefone: 713-745-8431
- E-mail: Ksharma2@MDAnderson.org
-
-
Maine
-
Augusta, Maine, Estados Unidos, 04330
- Recrutamento
- Harold Alfond Center for Cancer Care
-
Contato:
- Sandra Neptune, BSN, RN
- Número de telefone: 207-626-4811
- E-mail: sandra.neptune@mainegeneral.org
-
Investigador principal:
- Lindsay Hathaway, MD
-
Augusta, Maine, Estados Unidos, 04330
- Recrutamento
- Jackson Laboratory - Maine Cancer Genomics Initiative
-
Contato:
- Petra Helbig, CCRP
- Número de telefone: 207-664-4659
- E-mail: Petra.Helbig@jax.org
-
Investigador principal:
- Jens Rueter, MD
-
Belfast, Maine, Estados Unidos, 04915
- Recrutamento
- Waldo County General Hospital
-
Investigador principal:
- Roger Inhorn, MD
-
Contato:
- Jen - Dalton, MHA, BSN, RN
- Número de telefone: 2072948291
- E-mail: JDalton@mmc.org
-
Biddeford, Maine, Estados Unidos, 04005
- Recrutamento
- SMHC Cancer Care and Blood Disorders -Biddeford
-
Investigador principal:
- Roger Inhorn, MD
-
Contato:
- Jen - Dalton
- Número de telefone: 2072948291
- E-mail: JDalton@mmc.org
-
Brewer, Maine, Estados Unidos, 04412
- Recrutamento
- Northern Light Cancer Care
-
Investigador principal:
- Sarah Sinclair, MD
-
Contato:
- Carla Mancini, MHA, BSN, RN
- Número de telefone: 207-973-5581
- E-mail: cmancini@northernlight.org
-
Brewer, Maine, Estados Unidos, 04412
- Recrutamento
- Raish Peavey Haskell Children's Cancer and Treatment Center
-
Investigador principal:
- Sarah Sinclair, MD
-
Contato:
- Carla C Mancini, RN, BSN, OCN
- Número de telefone: 2079735581
- E-mail: cmancini@northernlight.org
-
Brunswick, Maine, Estados Unidos, 04011
- Recrutamento
- MaineHealth Cancer Care -Brunswick
-
Investigador principal:
- Roger Inhorn, MD
-
Contato:
- Jen - Dalton, MHA, BSN, RN
- Número de telefone: 2072948291
- E-mail: JDalton@mmc.org
-
Kennebunk, Maine, Estados Unidos, 04043
- Recrutamento
- New England Cancer Specialist
-
Investigador principal:
- Christian Thomas, MD
-
Contato:
- Patricia C Collins
- Número de telefone: 2073033422
- E-mail: collip@newecs.org
-
Kittery, Maine, Estados Unidos, 03904
- Recrutamento
- York Hopsital Oncology & Infusion Care in Kittery
-
Investigador principal:
- Marilyn McLaughlin, MD
-
Contato:
- Brenda i Kiberd, RN
- Número de telefone: 2073616115
- E-mail: Brenda.Kiberd@yorkhospital.com
-
Norway, Maine, Estados Unidos, 04268
- Recrutamento
- Stephens Memorial Hospital
-
Investigador principal:
- Roger Inhorn, MD
-
Contato:
- Jen - Dalton, MHA, BSN, RN
- Número de telefone: 2072948291
- E-mail: JDalton@mmc.org
-
Rockport, Maine, Estados Unidos, 04856
- Recrutamento
- Penobscot Bay Medical Center
-
Investigador principal:
- Roger Inhorn, MD
-
Contato:
- Jen - Dalton, MHA, BSN, RN
- Número de telefone: 2072948291
- E-mail: JDalton@mmc.org
-
Sanford, Maine, Estados Unidos, 04073
- Recrutamento
- SMHC Cancer Care and Blood Disorders -Sandford
-
Investigador principal:
- Roger Inhorn, MD
-
Contato:
- Jen - Dalton, MHA, BSN, RN
- Número de telefone: 2072948291
- E-mail: JDalton@mmc.org
-
Scarborough, Maine, Estados Unidos, 04074
- Recrutamento
- Maine Children's Cancer Program
-
Investigador principal:
- Roger Inhorn, MD
-
Contato:
- Jen - Dalton, MHA, BSN, RN
- Número de telefone: 2072948291
- E-mail: JDalton@mmc.org
-
Scarborough, Maine, Estados Unidos, 04074
- Recrutamento
- Maine Medical Partner's Women's Health
-
Investigador principal:
- Roger Inhorn, MD
-
Contato:
- Jen - Dalton, MHA, BSN, RN
- Número de telefone: 2072948291
- E-mail: JDalton@mmc.org
-
Scarborough, Maine, Estados Unidos, 04074
- Recrutamento
- New England Cancer Specialist
-
Investigador principal:
- Christian Thomas, MD
-
Contato:
- Patricia Collins, BA, CCRC
- Número de telefone: 207-303-3422
- E-mail: collip@newecs.org
-
South Portland, Maine, Estados Unidos, 04106
- Recrutamento
- MaineHealth Cancer Care -South Portland
-
Contato:
- Jen Dalton, MHA, BSN, RN
- Número de telefone: 207-294-8291
- E-mail: JDalton@mmc.org
-
Investigador principal:
- Roger Inhorn, MD
-
Topsham, Maine, Estados Unidos, 04086
- Recrutamento
- New England Cancer Specialist
-
Investigador principal:
- Christian Thomas, MD
-
Contato:
- Patricia C Collins, BA, CCRC
- Número de telefone: 12073033422
- E-mail: collip@newecs.org
-
Wells, Maine, Estados Unidos, 04090
- Recrutamento
- York Hospital Oncology & Infusion Care in Wells
-
Investigador principal:
- Marilyn McLaughlin, MD
-
Contato:
- Brenda Kiberd, RN
- Número de telefone: 207-361-6115
- E-mail: Brenda.Kiberd@yorkhospital.com
-
York Village, Maine, Estados Unidos, 03909
- Recrutamento
- York Hospital Oncology & Infusion Care in York
-
Investigador principal:
- Marilyn McLaughlin, MD
-
Contato:
- Brenda i Kiberd, RN
- Número de telefone: 2073616115
- E-mail: Brenda.Kiberd@yorkhospital.com
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Ativo, não recrutando
- University of Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48106
- Recrutamento
- Trinity Health Ann Arbor Hospital
-
Investigador principal:
- Elie Dib, MD
-
Contato:
- Número de telefone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Detroit, Michigan, Estados Unidos, 48236
- Recrutamento
- Henry Ford Health Saint John Hospital
-
Investigador principal:
- Carrie Dul, MD
-
Contato:
- Número de telefone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Flint, Michigan, Estados Unidos, 48503
- Recrutamento
- Genesys Hurley Cancer Institute
-
Investigador principal:
- Paul Adams, MD
-
Contato:
- Número de telefone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Recrutamento
- Cancer Research Consortium of West Michigan
-
Contato:
- Connie Szczepanek, RN
- Número de telefone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Kathleen J. Yost, MD
-
Lansing, Michigan, Estados Unidos, 48912
- Recrutamento
- University of Michigan Health - Sparrow Lansing
-
Investigador principal:
- Gordan Srkalovic, MD
-
Contato:
- Número de telefone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Livonia, Michigan, Estados Unidos, 48154
- Recrutamento
- Trinity Health Livonia Hospital
-
Investigador principal:
- Amit Mohindra, MD
-
Contato:
- Número de telefone: 7347127251
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Pontiac, Michigan, Estados Unidos, 48341
- Recrutamento
- Trinity Health Oakland Hospital
-
Investigador principal:
- Julie Goodman, MD
-
Contato:
- Número de telefone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Saginaw, Michigan, Estados Unidos, 48601
- Recrutamento
- MyMichigan Medical Center Saginaw
-
Investigador principal:
- Nicholas Damico, MD
-
Contato:
- Número de telefone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Traverse City, Michigan, Estados Unidos, 48341
- Recrutamento
- Michigan Cancer Research Consortium
-
Investigador principal:
- Philip Stella, MD
-
Contato:
- Beth LaVasseur, RN, MS
- Número de telefone: 734-712-7251
- E-mail: Beth.LaVasseur@stjoeshealth.org
-
Contato:
- Número de telefone: 877-590-5995
-
Warren, Michigan, Estados Unidos, 48093
- Recrutamento
- Henry Ford Health Warren Hospital
-
Investigador principal:
- Carrie Dul, MD
-
Contato:
- Número de telefone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68198
- Recrutamento
- University of Nebraska Medical Center
-
Investigador principal:
- Alissa Marr, MD
-
Contato:
- Micki Bethea, BS
- Número de telefone: 402-559-8011
- E-mail: mbethea@unmc.edu
-
-
New Hampshire
-
Concord, New Hampshire, Estados Unidos, 03103
- Recrutamento
- NH Oncology - Hematology, PA
-
Contato:
- Ali Fleury
- Número de telefone: 6033146888
- E-mail: A.Fleury@nhoh.com
-
Investigador principal:
- Michael Buff, MD
-
Manchester, New Hampshire, Estados Unidos, 03103
- Recrutamento
- Solinsky Center for Cancer Care
-
Contato:
- Ali Fleury, BA, CCRP
- Número de telefone: 603-314-6888
- E-mail: A.Fleury@nhoh.com
-
Investigador principal:
- Michael Buff, MD
-
Portsmouth, New Hampshire, Estados Unidos, 03801
- Recrutamento
- New England Cancer Specialist
-
Investigador principal:
- Christian Thomas, MD
-
Contato:
- Patricia C Collins, BA, CCRC
- Número de telefone: 2073033422
- E-mail: collip@newecs.org
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87110
- Recrutamento
- Presbyterian Kaseman Hospital
-
Investigador principal:
- Bernard Tawfik, MD
-
Contato:
- Monique Robertson, RN
- Número de telefone: (505)- 559-6100
- E-mail: mrobertso2@phs.org
-
Albuquerque, New Mexico, Estados Unidos, 87102
- Recrutamento
- Lovelace Medical Center - Saint Joseph Square
-
Investigador principal:
- Bernard Tawfik, MD
-
Contato:
- Leslie Byatt
- Número de telefone: (505) -925-0366
- E-mail: lpbyatt@salud.unm.edu
-
Albuquerque, New Mexico, Estados Unidos, 87131
- Recrutamento
- The University of New Mexico Comprehensive Cancer Center
-
Investigador principal:
- Bernard Tawfik, MD
-
Contato:
- Sheri Westgate, RN-BSN, OCN
- Número de telefone: (505) -925-0383
- E-mail: swestgate@salud.unm.edu
-
Las Cruces, New Mexico, Estados Unidos, 88011
- Recrutamento
- Memorial Medical Center
-
Investigador principal:
- Bernard Tawfik, MD
-
Contato:
- Kim Hoffman, RN
- Número de telefone: (575)- 556-6545
- E-mail: kim.hoffman@lpnt.net
-
Rio Rancho, New Mexico, Estados Unidos, 87124
- Recrutamento
- Presbyterian Rust Medical Center
-
Investigador principal:
- Bernard Tawfik, MD
-
Contato:
- Andrea Yost
- Número de telefone: (505) -253-7878
- E-mail: ayost3@phs.org
-
-
New York
-
Lake Success, New York, Estados Unidos, 11042
- Recrutamento
- Northwell Health Monter Cancer Center
-
Contato:
- Mary Agnes Templeton
- Número de telefone: 516-734-8979
- E-mail: mtempleton@northwell.edu
-
Investigador principal:
- Marina Frimer, MD
-
Mount Kisco, New York, Estados Unidos, 10549
- Recrutamento
- Northern Westchester Hospital
-
Investigador principal:
- Marina Frimer, MD
-
Contato:
- Jemima Jacob, MPH
- Número de telefone: 914-666-1366
- E-mail: jjacob22@northwell.edu
-
New Hyde Park, New York, Estados Unidos, 11040
- Recrutamento
- Cohen Children's Medical Center
-
Contato:
- Shreya Seepersaud
- Número de telefone: 718-470-7146
- E-mail: sseepersaud2@northwell.edu
-
Investigador principal:
- Marina Frimer, MD
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- Manhattan Eye, Ear, and Throat Hospital
-
Investigador principal:
- Marina Frimer, MD
-
Contato:
- Leila Nasr
- E-mail: lnasr@northwell.edu
-
New York, New York, Estados Unidos, 10305
- Recrutamento
- Staten Island University Hospital
-
Investigador principal:
- Marina Frimer, MD
-
Contato:
- Sammi Ruan
- Número de telefone: 718-226-1489
- E-mail: sruan2@northwell.edu
-
Contato:
- Melissa McCarthy
- Número de telefone: 718-226-1805
- E-mail: mccarthy22@northwell.edu
-
Rego Park, New York, Estados Unidos, 11374
- Recrutamento
- Queens Cancer Center
-
Investigador principal:
- Marina Frimer, MD
-
Contato:
- Harmandeep Kaur
- Número de telefone: 718-412-0773
- E-mail: hkaur37@northwell.edu
-
Sleepy Hollow, New York, Estados Unidos, 10591
- Recrutamento
- Phelps Hospital
-
Investigador principal:
- Marina Frimer, MD
-
Contato:
- Barbara Turner, RN
- Número de telefone: 914-269-1949
- E-mail: Bturner1@northwell.edu
-
Contato:
- Shyrley Gomez
- E-mail: Sgomez21@northwell.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- Recrutamento
- Lineberger Comprehensive Cancer Center
-
Investigador principal:
- Shetal Patel, MD
-
Contato:
- Emmie Cole
- Número de telefone: 919-966-4432
- E-mail: emmie_cole@med.unc.edu
-
Charlotte, North Carolina, Estados Unidos, 28277
- Recrutamento
- Atrium Health's Levine Cancer Institute
-
Investigador principal:
- Kathryn F. Mileham, MD, FACP
-
Contato:
- Jenna Gregory, MS, RN
- E-mail: Jenna.Gregory@atriumhealth.org
-
-
North Dakota
-
Bismarck, North Dakota, Estados Unidos, 58501
- Recrutamento
- Sanford Health- Bismarck
-
Contato:
- Peter Kurniali, MD
- Número de telefone: 701-323-5741
- E-mail: peter.kurniali@sanfordhealth.org
-
Investigador principal:
- Peter Kurniali, MD
-
Fargo, North Dakota, Estados Unidos, 58122
- Recrutamento
- Sanford Health- Fargo
-
Contato:
- Anu Gaba, MD
- Número de telefone: 701-234-6161
- E-mail: anu.gaba@sanfordhealth.org
-
Investigador principal:
- Anu Gaba, MD
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- Recrutamento
- University of Cincinnati Medical Center
-
Investigador principal:
- Davendra Sohal, MD
-
Contato:
- Kayla Webb, MSN, RN
- Número de telefone: 513-584-0599
- E-mail: webb2ka@ucmail.uc.edu
-
Kettering, Ohio, Estados Unidos, 45429
- Recrutamento
- Kettering Health
-
Contato:
- Allison Dymacek, BSN, RN
- Número de telefone: 937-395-8367
- E-mail: allison.dymacek@ketteringhealth.org
-
Investigador principal:
- Lex Leonhardt, DO
-
West Chester, Ohio, Estados Unidos, 45069
- Recrutamento
- West Chester Hospital
-
Investigador principal:
- Trisha Wise-Draper, MD
-
Contato:
- Kayla Webb, MSN, RN
- Número de telefone: 513-584-0599
- E-mail: webb2ka@ucmail.uc.edu
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97213
- Recrutamento
- Providence Health & Services
-
Investigador principal:
- Evthokia Hobbs, MD
-
Contato:
- Isa Ngirailemesang
- Número de telefone: 971-358-2056
- E-mail: Isa.Ngirailemesang@providence.org
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18103
- Recrutamento
- Lehigh Valley Hospital - Cedar Crest
-
Contato:
- Número de telefone: 734-712-3671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Investigador principal:
- Maged Khalil, MD
-
Bethlehem, Pennsylvania, Estados Unidos, 18017
- Recrutamento
- Lehigh Valley Hospital- Muhlenberg
-
Investigador principal:
- Maged Khalil, MD
-
Contato:
- Número de telefone: 7347127251
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
East Stroudsburg, Pennsylvania, Estados Unidos, 18301
- Recrutamento
- Pocono Medical Center
-
Investigador principal:
- Maged Khalil, MD
-
Contato:
- Número de telefone: 7347127251
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Hazleton, Pennsylvania, Estados Unidos, 18201
- Recrutamento
- Lehigh Valley Hospital-Hazleton
-
Investigador principal:
- Maged Khalil, MD
-
Contato:
- Número de telefone: 7347127251
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Philadelphia, Pennsylvania, Estados Unidos, 19111
- Recrutamento
- Fox Chase Cancer Center
-
Investigador principal:
- Margaret von Mehren, MD
-
Contato:
- Fathima S Sheriff
- Número de telefone: 215-728-4094
- E-mail: fathima.sheriff@fccc.edu
-
-
South Carolina
-
Bluffton, South Carolina, Estados Unidos, 29910
- Recrutamento
- SC Cancer Specialists at St. Joseph's/Candler Bluffton
-
Investigador principal:
- Mark Taylor, MD
-
Contato:
- Stephanie Smith, RN, MSN, OCN
- Número de telefone: 19128195723
- E-mail: smiths1@sjchs.org
-
Bluffton, South Carolina, Estados Unidos, 29910
- Recrutamento
- St. Joseph's/Candler Smith
-
Investigador principal:
- Mark Taylor, MD
-
Contato:
- Stephanie Smith, RN, MSN, OCN
- Número de telefone: 19128195723
- E-mail: smiths1@sjchs.org
-
Bluffton, South Carolina, Estados Unidos, 29910
- Recrutamento
- Summit Cancer Care at St. Josph's/Candler Bluffton
-
Investigador principal:
- Mark Taylor, MD
-
Contato:
- Stephanie Smith, RN, MSN, OCN
- Número de telefone: 19128195723
- E-mail: smiths1@sjchs.org
-
Hilton Head Island, South Carolina, Estados Unidos, 29926
- Recrutamento
- South Carolina Cancer Specialists
-
Investigador principal:
- Mark Taylor, MD
-
Contato:
- Stephanie Smith, RN, MSN, OCN
- Número de telefone: 19128195723
- E-mail: smiths1@sjchs.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57104
- Recrutamento
- Sanford Cancer Center Oncology Clinic and Pharmacy
-
Investigador principal:
- Steven Powell, MD
-
Contato:
- Steven Powell, MD
- Número de telefone: 605-328-8000
- E-mail: steven.powell@sanfordhealth.org
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Recrutamento
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute
-
Contato:
- Ethan Trull
- Número de telefone: 615-329-7274
- E-mail: Ethan.Trull@SarahCannon.com
-
Investigador principal:
- Meredith McKean, MD, MPH
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- The University of Texas MD Anderson Cancer Center
-
Investigador principal:
- Funda Meric-Bernstam, MD
-
Contato:
- Kshipra Sharma, MPH, MS
- Número de telefone: 713-745-8431
- E-mail: Ksharma2@MDAnderson.org
-
-
Utah
-
Cedar City, Utah, Estados Unidos, 84720
- Recrutamento
- Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center
-
Investigador principal:
- Ramya Thota, MD
-
Contato:
- Jake Kolu
- Número de telefone: 435-705-1632
- E-mail: Jake.Kolu@imail.org
-
Investigador principal:
- Derrick Haslem, MD
-
Salt Lake City, Utah, Estados Unidos, 84107
- Recrutamento
- Intermountain Healthcare
-
Contato:
- Tracy Taylor
- Número de telefone: 801-507-3953
- E-mail: tracy.taylor@imail.org
-
Investigador principal:
- Ramya Thota, M.D.
-
Investigador principal:
- Derrick Haslem, M.D.
-
St. George, Utah, Estados Unidos, 84770
- Recrutamento
- Dixie Regional Medical Center-River Road Campus
-
Investigador principal:
- Ramya Thota, MD
-
Contato:
- Jake Kolu
- Número de telefone: 435-705-1632
- E-mail: Jake.Kolu@imail.org
-
Investigador principal:
- Derrick Haslem, MD
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22042
- Recrutamento
- Inova Schar Cancer Institute
-
Investigador principal:
- Timothy Cannon, MD
-
Contato:
- Roxana Comfort, CRC
- Número de telefone: 571-472-0628
- E-mail: roxana.comfort@inova.org
-
-
Washington
-
Bonney Lake, Washington, Estados Unidos, 98391
- Recrutamento
- Northwest Medical Specialties
-
Contato:
- Jennifer Spokely
- Número de telefone: 253-999-3701
- E-mail: research@southsoundcare.org
-
Investigador principal:
- Frank Senecal, MD
-
Federal Way, Washington, Estados Unidos, 98003
- Recrutamento
- Northwest Medical Specialties
-
Contato:
- Jennifer Spokely
- Número de telefone: 253-999-3701
- E-mail: research@southsoundcare.org
-
Investigador principal:
- Frank Senecal, MD
-
Gig Harbor, Washington, Estados Unidos, 98332
- Recrutamento
- Northwest Medical Specialties
-
Contato:
- Jennifer Spokely
- Número de telefone: 253-999-3701
- E-mail: research@southsoundcare.org
-
Investigador principal:
- Frank Senecal, MD
-
Olympia, Washington, Estados Unidos, 98502
- Recrutamento
- Northwest Medical Specialties
-
Contato:
- Jennifer Spokely
- Número de telefone: 253-999-3701
- E-mail: research@southsoundcare.org
-
Investigador principal:
- Frank Senecal, MD
-
Puyallup, Washington, Estados Unidos, 98373
- Recrutamento
- Northwest Medical Specialties
-
Investigador principal:
- Frank Senecal, MD
-
Contato:
- Jennifer Spokely
- Número de telefone: 253-999-3701
- E-mail: reserch@southsoundcare.org
-
Seattle, Washington, Estados Unidos, 98104
- Recrutamento
- Swedish Cancer Institute
-
Investigador principal:
- Philip Gold, MD
-
Contato:
- Sidney Ching
- Número de telefone: 206-386-3142
- E-mail: sidney.ching@swedish.org
-
Tacoma, Washington, Estados Unidos, 98405
- Recrutamento
- Northwest Medical Specialties
-
Investigador principal:
- Frank Senecal, MD
-
Contato:
- Jennifer Spokely
- Número de telefone: 253-999-3701
- E-mail: reserch@southsoundcare.org
-
-
Wisconsin
-
Burlington, Wisconsin, Estados Unidos, 53105
- Recrutamento
- Aurora Cancer Care - Burlington
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Germantown, Wisconsin, Estados Unidos, 53022
- Recrutamento
- Aurora Health Care - Germantown Health Center
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Grafton, Wisconsin, Estados Unidos, 53024
- Recrutamento
- Aurora Cancer Care - Grafton
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Green Bay, Wisconsin, Estados Unidos, 54311
- Recrutamento
- Aurora BayCare Medical Center
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Kenosha, Wisconsin, Estados Unidos, 53142
- Recrutamento
- Aurora Cancer Care - Kenosha South
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Marinette, Wisconsin, Estados Unidos, 54143
- Recrutamento
- Aurora Bay Area Medical Center
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- Recrutamento
- Aurora St. Luke's Medical Center
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle M Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Estados Unidos, 53209
- Recrutamento
- Aurora Cancer Care Milwaukee
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle M Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Estados Unidos, 53223
- Recrutamento
- Aurora Sinai Medical Center
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Estados Unidos, 53227
- Recrutamento
- Aurora West Allis Medical Center
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Oshkosh, Wisconsin, Estados Unidos, 54904
- Recrutamento
- Vince Lombardi Cancer Clinic - Oshkosh
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Racine, Wisconsin, Estados Unidos, 53406
- Recrutamento
- Aurora Cancer Care - Racine
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Sheboygan, Wisconsin, Estados Unidos, 53081
- Recrutamento
- Vince Lombardi Cancer Center
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Summit, Wisconsin, Estados Unidos, 53066
- Recrutamento
- Aurora Medical Center in Summit
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Two Rivers, Wisconsin, Estados Unidos, 54241
- Recrutamento
- Vince Lombardi Cancer Clinic - Two Rivers
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle Toutloff, RN, CCRP
- Número de telefone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Wauwatosa, Wisconsin, Estados Unidos, 53226
- Recrutamento
- Aurora Cancer Care - Milwaukee West
-
Investigador principal:
- Antony Ruggeri, MD
-
Contato:
- Michelle Toutloff, RN, CCRP
- Número de telefone: 920-456-7880
- E-mail: Michelle.Martin2@aah.org
-
-
-
-
Puerto Rico
-
Cayey, Puerto Rico, Porto Rico, 00737
- Recrutamento
- PanOncology Trials
-
Contato:
- Natalia Ortiz
- Número de telefone: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Investigador principal:
- Maria Cruz Correa, MD
-
Dorado, Puerto Rico, Porto Rico, 00646
- Recrutamento
- PanOncology Trials
-
Contato:
- Natalia Ortiz
- Número de telefone: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Investigador principal:
- Maria Cruz Correa, MD
-
Manati, Puerto Rico, Porto Rico, 00674
- Recrutamento
- PanOncology Trials
-
Contato:
- Natalia Ortiz
- Número de telefone: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Investigador principal:
- Maria Crus Correa, MD
-
Mayagüez, Puerto Rico, Porto Rico, 00680
- Recrutamento
- PanOncology Trials
-
Contato:
- Natalia Ortiz
- Número de telefone: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Investigador principal:
- Maria Cruz Correa, MD
-
Ponce, Puerto Rico, Porto Rico, 00730
- Recrutamento
- PanOncology Trials
-
Contato:
- Natalia Ortiz
- Número de telefone: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Investigador principal:
- Maria Cruz Correa, MD
-
San Juan, Puerto Rico, Porto Rico, 00909
- Recrutamento
- PanOncology Trials
-
Contato:
- Natalia Ortiz
- Número de telefone: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Investigador principal:
- Maria Cruz Correa, MD
-
San Juan, Puerto Rico, Porto Rico, 00935
- Recrutamento
- PanOncology Trials
-
Contato:
- Natalia Ortiz
- Número de telefone: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Investigador principal:
- Maria Cruz Correa, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)
-
Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated (except under the circumstance in which the TAPUR arm is designed to provide additional evidence to support an existing FDA indication).
-
Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
-
Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:
- Absolute neutrophil count ≥ 1500 µl
- Hemoglobin ≥ 9.0 g/dl
- Platelets ≥ 75,000/µl
- Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
- Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
- Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
-
Patients must have disease that can be objectively measured by physical, laboratory or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma).
-
Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
-
Ability to understand and the willingness to sign a written informed consent/assent document.
-
Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
-
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
-
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study treatment, or completely abstain from sexual intercourse.
Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.
Exclusion Criteria:
- Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
- Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded
- Patients with previously treated brain metastases or previously treated leptomeningeal disease are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 1 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
- Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.
Note: there are additional exclusion criteria that may apply
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Group 5 (CSF1R,PDGFR,VEGFR)
Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations |
drug
Outros nomes:
|
|
Outro: Group 8 (ERBB2)
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
drug
Outros nomes:
|
|
Outro: Group 9 (BRAF V600E/D/K/R)
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations |
drug
Outros nomes:
|
|
Outro: Group 14 (BRCA1/2; ATM)
Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions |
drug
Outros nomes:
|
|
Outro: Group 16 (MSI-H, high mutational load and others)
Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations |
drug
Outros nomes:
|
|
Outro: Group 17 (CDKN2A, CDK4, CDK6)
Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation |
drug
Outros nomes:
|
|
Outro: Group 19 (BRCA1/2, PALB2)
Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations |
drug
Outros nomes:
|
|
Outro: Group 21 (BRCA1/2, PALB2, ATM, and others)
Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval |
drug
Outros nomes:
|
|
Outro: Group 24 (ERBB2)
Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
drug
Outros nomes:
|
|
Outro: Group 25
Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation |
drug
Outros nomes:
|
|
Outro: Group 26 (BRAF V600 E mutation )
Participants receive Dabrafenib plus Trametinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600 E mutation . |
Drug
Outros nomes:
|
|
Outro: Group 27 (ERBB2 amplification, ERBB2 (HER2) IHC2+ or IHC3+ overexpression)
Participants receive Fam-trastuzumab deruxtecan-nxki (ENHERTU®) - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification, For NSCLC Only-ERBB2 (HER2) IHC2+ or IHC3+ overexpression without ERBB2 amplification) |
Drug
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Prazo: Assessed at 16 weeks of treatment
|
Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used. |
Assessed at 16 weeks of treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall survival (OS)
Prazo: Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
|
OS will be estimated using the Kaplan-Meier method |
Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
|
Colaboradores e Investigadores
Publicações e links úteis
Publicações Gerais
- Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 Aug 1;39(22):2443-2451. doi: 10.1200/JCO.20.02923. Epub 2021 Apr 12.
- Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7.
- Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):743-750. doi: 10.1007/s11523-020-00752-8.
- Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 Oct;6:e2200306. doi: 10.1200/PO.22.00306.
- Mangat PK, Kirkwood MK, Hinshaw DC, Garrett-Mayer E, Schilsky RL. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study. NPJ Precis Oncol. 2025 Jul 3;9(1):222. doi: 10.1038/s41698-025-00962-1.
- Worden FP, Pisick E, Rothe M, Mangat PK, Garrett-Mayer E, Khalil MF, Carrizosa DR, Bauman JR, Leidner RS, Duvivier HL, Fu S, Park MS, Yost KJ, Calfa CJ, Marr AS, Balmanoukian AS, Behl D, Cannon TL, Nabell L, Powell SF, Thota R, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct;8:e2400477. doi: 10.1200/PO-24-00477. Epub 2024 Oct 16.
- Schuetze S, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Calfa CJ, Farrington LC, Livingston MB, Wentzel K, Behl D, Kier Y, Marr AS, von Mehren M, Press JZ, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul;8:e2400219. doi: 10.1200/PO.24.00219.
- Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Brouse G, Chan J, Mehmi I, Khalil M, Duvivier HL, Gaba A, Leuva H, Thota R, Yost KJ, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jun;8:e2400026. doi: 10.1200/PO.24.00026.
- Cannon TL, Rothe M, Mangat PK, Garrett-Mayer E, Chiu VK, Hwang J, Vijayvergia N, Alese OB, Dib EG, Duvivier HL, Klute KA, Sahai V, Ahn ER, Bedano P, Behl D, Sinclair S, Thota R, Urba WJ, Yang ES, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2024 Sep 20;42(27):3228-3237. doi: 10.1200/JCO.23.02078. Epub 2024 May 15.
- Perez JK, Kleber J, Rothe M, Mangat P, Garrett-Mayer E, Schilsky RL. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar;8:e2300615. doi: 10.1200/PO.23.00615.
- Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb;8:e2300513. doi: 10.1200/PO.23.00513.
- Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, Cannon TL, Powell S, Krauss JC, Reynolds CM, von Mehren M, Behl D, Calfa CJ, Duvivier HL, Kaplan HG, Livingston MB, Sharma MR, Urba WJ, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep;7:e2300385. doi: 10.1200/PO.23.00385.
- Rohatgi N, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Pisick E, Alese OB, Reynolds CM, Thota R, Vaccaro GM, von Mehren M, Arend RC, Chiu VK, Duvivier HL, Gold PJ, Hack K, Marr AS, Winer A, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep;7:e2300279. doi: 10.1200/PO.23.00279.
- Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2023 Nov 20;41(33):5140-5150. doi: 10.1200/JCO.23.00702. Epub 2023 Aug 10.
- Mangat PK, Garrett-Mayer E, Perez JK, Schilsky RL. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clin Trials. 2023 Dec;20(6):699-707. doi: 10.1177/17407745231182013. Epub 2023 Jul 25.
- Ganti AK, Rothe M, Mangat PK, Garrett-Mayer E, Dib EG, Duvivier HL, Ahn ER, Behl D, Borghaei H, Balmanoukian AS, Gaba A, Li R, Osei-Boateng K, Thota R, Grantham GN, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Jun;7:e2300041. doi: 10.1200/PO.23.00041.
- Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J, Maitland ML, Patel SR, Reese Z, Balmanoukian AS, Drescher CW, Li R, Tsimberidou AM, Leath CA 3rd, O'Lone R, Grantham GN, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Apr;7:e2200609. doi: 10.1200/PO.22.00609.
- Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, Dib E, Burgess EF, Zakem M, Rohatgi N, Bilen MA, O'Lone R, Grantham GN, Schilsky RL. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Feb;7:e2200505. doi: 10.1200/PO.22.00505.
- Carrizosa DR, Rothe M, Mangat PK, Garrett-Mayer E, Behl D, Adesunloye B, Pisick E, Beekman KW, Dotan E, Akce M, Alese OB, Sahai V, Klute KA, Aragon-Ching JB, Cooper KA, Thota R, Meric-Bernstam F, Hosein PJ, Maestas EC, Moyers JT, Powell S, Zhao S, Hobbs E, Rueter J, Sohal DPS, Taylor MA, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Jan;10:e2500716. doi: 10.1200/PO-25-00716. Epub 2026 Jan 15.
- Al Baghdadi T, Rothe M, Mangat PK, Garrett-Mayer E, Crysler OV, Mileham KF, Farrington LC, Adesunloye B, Dublis SA, Astsaturov I, Calfa CJ, Bleeker J, Khalil M, Thota R, Cannon TL, Alese OB, Gold PJ, Hafez N, Baron AD, Meric-Bernstam F, Hobbs E, Marr AS, Rueter J, Tawfik B, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2025 Oct;9:e2500649. doi: 10.1200/PO-25-00649. Epub 2025 Oct 16.
- Cobain EF, Rothe M, Garrett-Mayer E, Cannon TL, Chan JK, Mileham KF, Adesunloye B, Calfa CJ, Alese OB, Butler KY, Dib EG, Pisick E, Bell M, Klute KA, Mehmi I, Meric-Bernstam F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Apr;10(4):e2501205. doi: 10.1200/PO-25-01205. Epub 2026 Apr 30.
- Pisick E, Rothe M, Garrett-Mayer E, Srkalovic G, Chan JK, Calfa CJ, Leath CA 3rd, Marr AS, Gold PJ, Crane EK, Moyers JT, Yost Butler K, Gaba A, Thota R, Harnden KK, Alese OB, Jain A, Rueter J, Gill S, George TJ, Frimer M, Kayali F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Apr;10(4):e2500985. doi: 10.1200/PO-25-00985. Epub 2026 Apr 22.
- Veljovich DS, Rothe M, Garrett-Mayer E, Ali-Ahmad HM, Naumann RW, Siedel J, Chan JK, Gregory A, Pisick E, Adesunloye B, Arend RC, Bell M, Frimer M, Tawfik B, Thota R, Tsimberidou AM, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Jul;10(7):e2600456. doi: 10.1200/PO-26-00456. Epub 2026 Jul 15.
- Diamond-Rossi SA, Rothe M, Garrett-Mayer E, Pisick E, Bleeker J, Ganti AK, Meric-Bernstam F, Moyers JT, Nair SG, Kadakia KC, Rohatgi N, Sahai V, Vijayvergia N, Gold PJ, Sharma MR, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study. JCO Precis Oncol. 2026 Oct;10(10):e2600703. doi: 10.1200/PO-26-00703. Epub 2026 Oct 16.
- Srkalovic G, Rothe M, Garrett-Mayer E, Mileham KF, Adesunloye B, Pisick E, Leath CA 3rd, Colocci N, Chen MD, Meric-Bernstam F, Marr AS, Alese OB, Powell S, Rueter J, Benyounes A, Pontious C, Lewis MA, Thomas GW, Kier Y, Calfa CJ, von Mehren M, Acoba JD, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Oct;10(10):e2600454. doi: 10.1200/PO-26-00454. Epub 2026 Oct 7.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Vasculares
- Doenças cardiovasculares
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Linfoma
- Neoplasias de Células Plasmáticas
- Distúrbios hemostáticos
- Paraproteinemias
- Distúrbios das Proteínas Sanguíneas
- Distúrbios hemorrágicos
- Doenças hemic e linfáticas
- Neoplasias
- Mieloma múltiplo
- Linfoma Não-Hodgkin
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Compostos de enxofre
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Azoles
- Amidas
- Indoles
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Pirróis
- Sulfonamidas
- Sulfonas
- Trastuzumabe
- Sunitinibe
- Nivolumabe
- Ipilimumabe
- Vemurafenibe
- abemaciclib
- Pertuzumab
- Dabrafenib
- Trametinibe
- Atezolizumab
- Olaparibe
- Talazoparibe
- Cobimetinibe
- Tucatinibe
- Futibatinib
Outros números de identificação do estudo
- Pro00014171
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .